Canaccord raised the firm’s price target on AngioDynamics (ANGO) to $15 from $12 and keeps a Buy rating on the shares. AngioDynamics reported one of its strongest quarters in recent memory, the analyst tells investors in a research note. The firm back-end loaded its NanoKnife expectations for this fiscal year, but thinks in the long-term it could provide significant growth for AngioDynamics. It sees thrombectomy acceleration today with improving profitability.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- AngioDynamics, Inc. Reports Growth in Med Tech Segment
- Morning Movers: AngioDynamics jumps following results and guidance raise
- AngioDynamics Hosts Virtual NanoKnife Investor Event
- AngioDynamics Reports Growth and Advances NanoKnife System
- Options Volatility and Implied Earnings Moves Today, January 08, 2025